(en) Steven P. Marso, Stephen C. Bain, Agostino Consoli et Freddy G. Eliaschewitz, « Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 375, no 19, , p. 1834–1844 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1607141, lire en ligne, consulté le )
(en) John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et Melanie Davies, « Once-Weekly Semaglutide in Adults with Overweight or Obesity », New England Journal of Medicine, vol. 384, no 11, , p. 989–1002 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2032183, lire en ligne, consulté le )
(en) Elie Dolgin, « Weight-loss-drug pioneer: this biochemist finally gained recognition for her work », Nature, vol. 624, no 7992, , p. 506–506 (DOI10.1038/d41586-023-03927-1, lire en ligne, consulté le )
Christopher Sorli, Shin-ichi Harashima, George M Tsoukas et Jeffrey Unger, « Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 4, , p. 251–260 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30013-X, lire en ligne, consulté le )
Bo Ahrén, Luis Masmiquel, Harish Kumar et Mehmet Sargin, « Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 341–354 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30092-X, lire en ligne, consulté le )
Vanita R Aroda, Stephen C Bain, Bertrand Cariou et Milivoj Piletič, « Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 355–366 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30085-2, lire en ligne, consulté le )
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan et Ofri Mosenzon, « Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial », The Lancet, vol. 392, no 10148, , p. 637–649 (ISSN0140-6736, DOI10.1016/S0140-6736(18)31773-2, lire en ligne, consulté le )
(en) Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et Alicja Wizert, « The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity », Diabetes, Obesity and Metabolism, vol. 23, no 3, , p. 754–762 (ISSN1462-8902 et 1463-1326, PMID33269530, PMCIDPMC7898914, DOI10.1111/dom.14280, lire en ligne, consulté le )
Gunther Wong et Gitanjali Srivastava, « Obesity Management in Children and Adolescents », Gastroenterology Clinics of North America, management of Obesity, Part I: Overview and Basic Mechanisms, vol. 52, no 2, , p. 443–455 (ISSN0889-8553, DOI10.1016/j.gtc.2023.03.011, lire en ligne, consulté le )
(en) William R. Clarke et Ronald M. Lauer, « Does childhood obesity track into adulthood? », Critical Reviews in Food Science and Nutrition, vol. 33, nos 4-5, , p. 423–430 (ISSN1040-8398 et 1549-7852, DOI10.1080/10408399309527641, lire en ligne, consulté le )
(en) A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun et John Deanfield, « Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes », New England Journal of Medicine, vol. 389, no 24, , p. 2221–2232 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2307563, lire en ligne, consulté le )
(en) Vlado Perkovic, Katherine R. Tuttle, Peter Rossing et Kenneth W. Mahaffey, « Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 391, no 2, , p. 109–121 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2403347, lire en ligne, consulté le )
(en) Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et Martin Linder, « A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis », New England Journal of Medicine, vol. 384, no 12, , p. 1113–1124 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2028395, lire en ligne, consulté le )
Hanna Clementine Tan, Oliver Allan Dampil et Maricar Mae Marquez, « Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis », Journal of the ASEAN Federation of Endocrine Societies, vol. 37, no 2, , p. 65–72 (ISSN2308-118X, PMID36578889, PMCID9758543, DOI10.15605/jafes.037.02.14, lire en ligne, consulté le ).
Liyun He, Jialu Wang, Fan Ping et Na Yang, « Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials », JAMA Internal Medicine, vol. 182, no 5, , p. 513–519 (ISSN2168-6106, DOI10.1001/jamainternmed.2022.0338, lire en ligne, consulté le )
(en) Berit Østergaard Christoffersen, Guillermo Sanchez‐Delgado, Linu Mary John et Donna H. Ryan, « Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss », Obesity, vol. 30, no 4, , p. 841–857 (ISSN1930-7381 et 1930-739X, PMID35333444, PMCIDPMC9310705, DOI10.1002/oby.23374, lire en ligne, consulté le ).
elsevier.com
linkinghub.elsevier.com
Gunther Wong et Gitanjali Srivastava, « Obesity Management in Children and Adolescents », Gastroenterology Clinics of North America, management of Obesity, Part I: Overview and Basic Mechanisms, vol. 52, no 2, , p. 443–455 (ISSN0889-8553, DOI10.1016/j.gtc.2023.03.011, lire en ligne, consulté le )
(en) Steven P. Marso, Stephen C. Bain, Agostino Consoli et Freddy G. Eliaschewitz, « Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 375, no 19, , p. 1834–1844 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1607141, lire en ligne, consulté le )
(en) John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et Melanie Davies, « Once-Weekly Semaglutide in Adults with Overweight or Obesity », New England Journal of Medicine, vol. 384, no 11, , p. 989–1002 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2032183, lire en ligne, consulté le )
Christopher Sorli, Shin-ichi Harashima, George M Tsoukas et Jeffrey Unger, « Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 4, , p. 251–260 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30013-X, lire en ligne, consulté le )
Bo Ahrén, Luis Masmiquel, Harish Kumar et Mehmet Sargin, « Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 341–354 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30092-X, lire en ligne, consulté le )
Vanita R Aroda, Stephen C Bain, Bertrand Cariou et Milivoj Piletič, « Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 355–366 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30085-2, lire en ligne, consulté le )
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan et Ofri Mosenzon, « Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial », The Lancet, vol. 392, no 10148, , p. 637–649 (ISSN0140-6736, DOI10.1016/S0140-6736(18)31773-2, lire en ligne, consulté le )
(en) Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et Alicja Wizert, « The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity », Diabetes, Obesity and Metabolism, vol. 23, no 3, , p. 754–762 (ISSN1462-8902 et 1463-1326, PMID33269530, PMCIDPMC7898914, DOI10.1111/dom.14280, lire en ligne, consulté le )
Gunther Wong et Gitanjali Srivastava, « Obesity Management in Children and Adolescents », Gastroenterology Clinics of North America, management of Obesity, Part I: Overview and Basic Mechanisms, vol. 52, no 2, , p. 443–455 (ISSN0889-8553, DOI10.1016/j.gtc.2023.03.011, lire en ligne, consulté le )
(en) William R. Clarke et Ronald M. Lauer, « Does childhood obesity track into adulthood? », Critical Reviews in Food Science and Nutrition, vol. 33, nos 4-5, , p. 423–430 (ISSN1040-8398 et 1549-7852, DOI10.1080/10408399309527641, lire en ligne, consulté le )
(en) A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun et John Deanfield, « Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes », New England Journal of Medicine, vol. 389, no 24, , p. 2221–2232 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2307563, lire en ligne, consulté le )
(en) Vlado Perkovic, Katherine R. Tuttle, Peter Rossing et Kenneth W. Mahaffey, « Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 391, no 2, , p. 109–121 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2403347, lire en ligne, consulté le )
(en) Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et Martin Linder, « A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis », New England Journal of Medicine, vol. 384, no 12, , p. 1113–1124 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2028395, lire en ligne, consulté le )
Hanna Clementine Tan, Oliver Allan Dampil et Maricar Mae Marquez, « Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis », Journal of the ASEAN Federation of Endocrine Societies, vol. 37, no 2, , p. 65–72 (ISSN2308-118X, PMID36578889, PMCID9758543, DOI10.15605/jafes.037.02.14, lire en ligne, consulté le ).
Liyun He, Jialu Wang, Fan Ping et Na Yang, « Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials », JAMA Internal Medicine, vol. 182, no 5, , p. 513–519 (ISSN2168-6106, DOI10.1001/jamainternmed.2022.0338, lire en ligne, consulté le )
(en) Berit Østergaard Christoffersen, Guillermo Sanchez‐Delgado, Linu Mary John et Donna H. Ryan, « Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss », Obesity, vol. 30, no 4, , p. 841–857 (ISSN1930-7381 et 1930-739X, PMID35333444, PMCIDPMC9310705, DOI10.1002/oby.23374, lire en ligne, consulté le ).
jamanetwork.com
Liyun He, Jialu Wang, Fan Ping et Na Yang, « Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials », JAMA Internal Medicine, vol. 182, no 5, , p. 513–519 (ISSN2168-6106, DOI10.1001/jamainternmed.2022.0338, lire en ligne, consulté le )
lemonde.fr
« Wegovy, le médicament vedette contre l’obésité de Novo Nordisk, est lancé en France », Le Monde, (lire en ligne, consulté le )
« Les effets indésirables de l’Ozempic, cet antidiabétique détourné pour maigrir, de mieux en mieux mesurés », Le Monde, (lire en ligne, consulté le )
« Dans une clinique des Etats-Unis, la révolution des médicaments anti-obésité en marche : « Je suis passée de 107 kilos à 52 kilos » en neuf mois », Le Monde, (lire en ligne, consulté le )
literatumonline.com
dom-pubs.pericles-prod.literatumonline.com
(en) Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et Alicja Wizert, « The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity », Diabetes, Obesity and Metabolism, vol. 23, no 3, , p. 754–762 (ISSN1462-8902 et 1463-1326, PMID33269530, PMCIDPMC7898914, DOI10.1111/dom.14280, lire en ligne, consulté le )
(en) Elie Dolgin, « Weight-loss-drug pioneer: this biochemist finally gained recognition for her work », Nature, vol. 624, no 7992, , p. 506–506 (DOI10.1038/d41586-023-03927-1, lire en ligne, consulté le )
nejm.org
(en) Steven P. Marso, Stephen C. Bain, Agostino Consoli et Freddy G. Eliaschewitz, « Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 375, no 19, , p. 1834–1844 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa1607141, lire en ligne, consulté le )
(en) John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et Melanie Davies, « Once-Weekly Semaglutide in Adults with Overweight or Obesity », New England Journal of Medicine, vol. 384, no 11, , p. 989–1002 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2032183, lire en ligne, consulté le )
(en) A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun et John Deanfield, « Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes », New England Journal of Medicine, vol. 389, no 24, , p. 2221–2232 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2307563, lire en ligne, consulté le )
(en) Vlado Perkovic, Katherine R. Tuttle, Peter Rossing et Kenneth W. Mahaffey, « Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes », New England Journal of Medicine, vol. 391, no 2, , p. 109–121 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2403347, lire en ligne, consulté le )
(en) Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi et Martin Linder, « A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis », New England Journal of Medicine, vol. 384, no 12, , p. 1113–1124 (ISSN0028-4793 et 1533-4406, DOI10.1056/NEJMoa2028395, lire en ligne, consulté le )
nih.gov
ncbi.nlm.nih.gov
(en) Martin Friedrichsen, Astrid Breitschaft, Sayeh Tadayon et Alicja Wizert, « The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity », Diabetes, Obesity and Metabolism, vol. 23, no 3, , p. 754–762 (ISSN1462-8902 et 1463-1326, PMID33269530, PMCIDPMC7898914, DOI10.1111/dom.14280, lire en ligne, consulté le )
Hanna Clementine Tan, Oliver Allan Dampil et Maricar Mae Marquez, « Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis », Journal of the ASEAN Federation of Endocrine Societies, vol. 37, no 2, , p. 65–72 (ISSN2308-118X, PMID36578889, PMCID9758543, DOI10.15605/jafes.037.02.14, lire en ligne, consulté le ).
(en) Berit Østergaard Christoffersen, Guillermo Sanchez‐Delgado, Linu Mary John et Donna H. Ryan, « Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss », Obesity, vol. 30, no 4, , p. 841–857 (ISSN1930-7381 et 1930-739X, PMID35333444, PMCIDPMC9310705, DOI10.1002/oby.23374, lire en ligne, consulté le ).
pubmed.ncbi.nlm.nih.gov
Hanna Clementine Tan, Oliver Allan Dampil et Maricar Mae Marquez, « Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis », Journal of the ASEAN Federation of Endocrine Societies, vol. 37, no 2, , p. 65–72 (ISSN2308-118X, PMID36578889, PMCID9758543, DOI10.15605/jafes.037.02.14, lire en ligne, consulté le ).
Christopher Sorli, Shin-ichi Harashima, George M Tsoukas et Jeffrey Unger, « Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 4, , p. 251–260 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30013-X, lire en ligne, consulté le )
Bo Ahrén, Luis Masmiquel, Harish Kumar et Mehmet Sargin, « Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 341–354 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30092-X, lire en ligne, consulté le )
Vanita R Aroda, Stephen C Bain, Bertrand Cariou et Milivoj Piletič, « Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial », The Lancet Diabetes & Endocrinology, vol. 5, no 5, , p. 355–366 (ISSN2213-8587, DOI10.1016/S2213-8587(17)30085-2, lire en ligne, consulté le )
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan et Ofri Mosenzon, « Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial », The Lancet, vol. 392, no 10148, , p. 637–649 (ISSN0140-6736, DOI10.1016/S0140-6736(18)31773-2, lire en ligne, consulté le )
(en) William R. Clarke et Ronald M. Lauer, « Does childhood obesity track into adulthood? », Critical Reviews in Food Science and Nutrition, vol. 33, nos 4-5, , p. 423–430 (ISSN1040-8398 et 1549-7852, DOI10.1080/10408399309527641, lire en ligne, consulté le )
wiley.com
onlinelibrary.wiley.com
(en) Berit Østergaard Christoffersen, Guillermo Sanchez‐Delgado, Linu Mary John et Donna H. Ryan, « Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss », Obesity, vol. 30, no 4, , p. 841–857 (ISSN1930-7381 et 1930-739X, PMID35333444, PMCIDPMC9310705, DOI10.1002/oby.23374, lire en ligne, consulté le ).